CoChat

Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes

Open access
Hulot, Jean-Sébastien, Stillitano, Francesca, Salem, Jo Elie, Kovacic, Jason C, Fuster, Valentin, Hajjar, Roger J · 2014 · Stem Cell Research & Therapy
Cited by 126

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Pluripotent stem cells (PSCs) represent an appealing source from which to develop cell replacement therapies. Different initiatives have been launched to promote their development toward clinical applications. This article will review the main questions that should be considered before translating PSC-derived cardiomyocytes into clinical investigations, including the development of good manufacturing practice-level PSC lines, the development of efficient protocols to generate pure populations of cardiac myocytes, and the development of techniques to improve the retention and survival rate of transplanted cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/scrt390

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 50

  1. Garbern JC, Lee RT: Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell. 2013, 12: 689-698. 10.1016/j.stem.2013.05.008. · DOI · Paper page
  2. Taylor DA: Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure. Curr Control Trials Cardiovasc Med. 2001, 2: 208-210. 10.1186/CVM-2-5-208. · doi:10.1186/cvm-2-5-208
  3. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 1995, 85: 3048-3057. · DOI · Paper page
  4. Schuleri KH, Feigenbaum GS, Centola M, Weiss ES, Zimmet JM, Turney J, Kellner J, Zviman MM, Hatzistergos KE, Detrick B, Conte JV, McNiece I, Steenbergen C, Lardo AC, Hare JM: Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009, 30: 2722-2732. 10.1093/eurheartj/ehp265. · DOI · Paper page
  5. Schenke-Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan-Hagvall S, Gekas C, Zhang R, Goldhaber JI, Mikkola HK, Plath K, MacLellan WR: Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells. 2008, 26: 1537-1546. 10.1634/stemcells.2008-0033. · DOI · Paper page
  6. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK: Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008, 118: 498-506. 10.1161/CIRCULATIONAHA.108.769562. · DOI · Paper page
  7. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ: Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009, 104: e30-e41. 10.1161/CIRCRESAHA.108.192237. · DOI · Paper page
  8. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM: Embryonic stem cell lines derived from human blastocysts. Science. 1998, 282: 1145-1147. · DOI · Paper page
  9. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019. · DOI · Paper page
  10. Grskovic M, Javaherian A, Strulovici B, Daley GQ: Induced pluripotent stem cells - opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011, 10: 915-929. · DOI · Paper page
  11. Garber K: Inducing translation. Nat Biotechnol. 2013, 31: 483-486. 10.1038/nbt.2602. · DOI
  12. Unger C, Skottman H, Blomberg P, Dilber MS, Hovatta O: Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet. 2008, 17: R48-R53. 10.1093/hmg/ddn079. · DOI · Paper page
  13. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O'Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE: Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007, 25: 1015-1024. 10.1038/nbt1327. · DOI · Paper page
  14. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V, Rucker-Martin C, Barbry P, Bel A, Bruneval P, Cowan C, Pouly J, Mitalipov S, Gouadon E, Binder P, Hagege A, Desnos M, Renaud JF, Menasche P, Puceat M: A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest. 2010, 120: 1125-1139. 10.1172/JCI40120. · DOI · Paper page
  15. Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, Murry CE: Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007, 21: 1345-1357. 10.1096/fj.06-6769com. · DOI · Paper page
  16. Lister R, Pelizzola M, Kida YS, Hawkins RD, Nery JR, Hon G, Antosiewicz-Bourget J, O'Malley R, Castanon R, Klugman S, Downes M, Yu R, Stewart R, Ren B, Thomson JA, Evans RM, Ecker JR: Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011, 471: 68-73. 10.1038/nature09798. · DOI · Paper page
  17. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, Gepstein L: Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol. 2004, 22: 1282-1289. 10.1038/nbt1014. · DOI · Paper page
  18. Xu C, Police S, Rao N, Carpenter MK: Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002, 91: 501-508. 10.1161/01.RES.0000035254.80718.91. · DOI · Paper page
  19. Zhu WZ, Van Biber B, Laflamme MA: Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells. Methods Mol Biol. 2011, 767: 419-431. 10.1007/978-1-61779-201-4_31. · DOI
  20. Ren Y, Lee MY, Schliffke S, Paavola J, Amos PJ, Ge X, Ye M, Zhu S, Senyei G, Lum L, Ehrlich BE, Qyang Y: Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J Mol Cell Cardiol. 2011, 51: 280-287. 10.1016/j.yjmcc.2011.04.012. · DOI · Paper page
  21. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG, Gramolini A, Keller G: SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol. 2011, 29: 1011-1018. 10.1038/nbt.2005. · DOI · Paper page
  22. Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, Hashimoto H, Suzuki T, Yamashita H, Satoh Y, Egashira T, Seki T, Muraoka N, Yamakawa H, Ohgino Y, Tanaka T, Yoichi M, Yuasa S, Murata M, Suematsu M, Fukuda K: Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2013, 12: 127-137. 10.1016/j.stem.2012.09.013. · DOI · Paper page
  23. Hattori F, Chen H, Yamashita H, Tohyama S, Satoh YS, Yuasa S, Li W, Yamakawa H, Tanaka T, Onitsuka T, Shimoji K, Ohno Y, Egashira T, Kaneda R, Murata M, Hidaka K, Morisaki T, Sasaki E, Suzuki T, Sano M, Makino S, Oikawa S, Fukuda K: Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods. 2010, 7: 61-66. 10.1038/nmeth.1403. · DOI · Paper page
  24. Buta C, David R, Dressel R, Emgard M, Fuchs C, Gross U, Healy L, Hescheler J, Kolar R, Martin U, Mikkers H, Muller FJ, Schneider RK, Seiler AE, Spielmann H, Weitzer G: Reconsidering pluripotency tests: do we still need teratoma assays?. Stem Cell Res. 2013, 11: 552-562. 10.1016/j.scr.2013.03.001. · DOI · Paper page
  25. Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S, Puri PL, Leone TC, Marine JE, Calkins H, Kelly DP, Judge DP, Chen HS: Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013, 494: 105-110. 10.1038/nature11799. · DOI · Paper page
  26. van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C, den Ouden K, Ward-van Oostwaard D, Korving J, Tertoolen LG, van Echteld CJ, Doevendans PA, Mummery CL: Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007, 1: 9-24. 10.1016/j.scr.2007.06.001. · DOI · Paper page
  27. de Almeida PE, Ransohoff JD, Nahid A, Wu JC: Immunogenicity of pluripotent stem cells and their derivatives. Circ Res. 2013, 112: 549-561. 10.1161/CIRCRESAHA.111.249243. · DOI
  28. Draper JS, Pigott C, Thomson JA, Andrews PW: Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat. 2002, 200: 249-258. 10.1046/j.1469-7580.2002.00030.x. · DOI · Paper page
  29. Drukker M: Recent advancements towards the derivation of immune-compatible patient-specific human embryonic stem cell lines. Semin Immunol. 2008, 20: 123-129. 10.1016/j.smim.2007.11.002. · DOI
  30. Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, Reubinoff B, Mandelboim O, Benvenisty N: Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A. 2002, 99: 9864-9869. 10.1073/pnas.142298299. · DOI · Paper page
  31. Drukker M, Benvenisty N: The immunogenicity of human embryonic stem-derived cells. Trends Biotechnol. 2004, 22: 136-141. 10.1016/j.tibtech.2004.01.003. · DOI · Paper page
  32. Kim K, Lerou P, Yabuuchi A, Lengerke C, Ng K, West J, Kirby A, Daly MJ, Daley GQ: Histocompatible embryonic stem cells by parthenogenesis. Science. 2007, 315: 482-486. 10.1126/science.1133542. · DOI · Paper page
  33. Revazova ES, Turovets NA, Kochetkova OD, Agapova LS, Sebastian JL, Pryzhkova MV, Smolnikova VI, Kuzmichev LN, Janus JD: HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 2008, 10: 11-24. 10.1089/clo.2007.0063. · doi:10.1089/clo.2007.0063
  34. Zhao T, Zhang ZN, Rong Z, Xu Y: Immunogenicity of induced pluripotent stem cells. Nature. 2011, 474: 212-215. 10.1038/nature10135. · DOI · Paper page
  35. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shioda T, Hochedlinger K: Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature. 2010, 465: 175-181. 10.1038/nature09017. · DOI · Paper page
  36. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, Sugiura M, Ideno H, Shimada A, Nifuji A, Abe M: Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013, 494: 100-104. 10.1038/nature11807. · DOI · Paper page
  37. Zimmermann A, Preynat-Seauve O, Tiercy JM, Krause KH, Villard J: Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev. 2012, 21: 2364-2373. 10.1089/scd.2012.0088. · DOI · Paper page
  38. Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE: Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005, 167: 663-671. 10.1016/S0002-9440(10)62041-X. · DOI · Paper page
  39. Qiao H, Surti S, Choi SR, Raju K, Zhang H, Ponde DE, Kung HF, Karp J, Zhou R: Death and proliferation time course of stem cells transplanted in the myocardium. Mol Imaging Biol. 2009, 11: 408-414. 10.1007/s11307-009-0222-3. · DOI
  40. Shiba Y, Fernandes S, Zhu WZ, Filice D, Muskheli V, Kim J, Palpant NJ, Gantz J, Moyes KW, Reinecke H, Van Biber B, Dardas T, Mignone JL, Izawa A, Hanna R, Viswanathan M, Gold JD, Kotlikoff MI, Sarvazyan N, Kay MW, Murry CE, Laflamme MA: Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature. 2012, 489: 322-325. 10.1038/nature11317. · DOI · Paper page
  41. Li X, Zhang F, Song G, Gu W, Chen M, Yang B, Li D, Wang D, Cao K: Intramyocardial injection of pig pluripotent stem cells improves left ventricular function and perfusion: a study in a porcine model of acute myocardial infarction. PLoS One. 2013, 8: e66688-10.1371/journal.pone.0066688. · DOI
  42. Xiong Q, Ye L, Zhang P, Lepley M, Tian J, Li J, Zhang L, Swingen C, Vaughan JT, Kaufman DS, Zhang J: Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation. 2013, 127: 997-1008. 10.1161/CIRCULATIONAHA.112.000641. · DOI
  43. Terrovitis JV, Smith RR, Marban E: Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010, 106: 479-494. 10.1161/CIRCRESAHA.109.208991. · DOI · Paper page
  44. Didie M, Christalla P, Rubart M, Muppala V, Doker S, Unsold B, El-Armouche A, Rau T, Eschenhagen T, Schwoerer AP, Ehmke H, Schumacher U, Fuchs S, Lange C, Becker A, Tao W, Scherschel JA, Soonpaa MH, Yang T, Lin Q, Zenke M, Han DW, Scholer HR, Rudolph C, Steinemann D, Schlegelberger B, Kattman S, Witty A, Keller G, Field LJ: Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013, 123: 1285-1298. 10.1172/JCI66854. · DOI
  45. Bel A, Planat-Bernard V, Saito A, Bonnevie L, Bellamy V, Sabbah L, Bellabas L, Brinon B, Vanneaux V, Pradeau P, Peyrard S, Larghero J, Pouly J, Binder P, Garcia S, Shimizu T, Sawa Y, Okano T, Bruneval P, Desnos M, Hagege AA, Casteilla L, Puceat M, Menasche P: Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Circulation. 2010, 122: S118-S123. 10.1161/CIRCULATIONAHA.109.927293. · DOI · Paper page
  46. Wang Y, Zhang WY, Hu S, Lan F, Lee AS, Huber B, Lisowski L, Liang P, Huang M, de Almeida PE, Won JH, Sun N, Robbins RC, Kay MA, Urnov FD, Wu JC: Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res. 2012, 111: 1494-1503. 10.1161/CIRCRESAHA.112.274969. · DOI · Paper page
  47. Campan M, Lionetti V, Aquaro GD, Forini F, Matteucci M, Vannucci L, Chiuppesi F, Di Cristofano C, Faggioni M, Maioli M, Barile L, Messina E, Lombardi M, Pucci A, Pistello M, Recchia FA: Ferritin as a reporter gene for in vivo tracking of stem cells by 1.5-T cardiac MRI in a rat model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2011, 300: H2238-H2250. 10.1152/ajpheart.00935.2010. · DOI · Paper page
  48. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC: Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res. 2013, 112: 165-173. 10.1161/CIRCRESAHA.112.276519. · DOI · Paper page
  49. Assmus B, Zeiher AM: Early cardiac retention of administered stem cells determines clinical efficacy of cell therapy in patients with dilated cardiomyopathy. Circ Res. 2013, 112: 6-8. 10.1161/CIRCRESAHA.112.300341. · doi:10.1161/circresaha.112.300341
  50. Dow J, Simkhovich BZ, Kedes L, Kloner RA: Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc Res. 2005, 67: 301-307. 10.1016/j.cardiores.2005.04.011. · DOI · Paper page

Cited by

Metadata

Authors
Hulot, J.-S., Stillitano, F., Salem, J. E., Kovacic, J. C., Fuster, V., & Hajjar, R. J.
Venue
Stem Cell Research & Therapy
Published
2014-01-09
Volume
5
Issue
1
Pages
1-1
ISSN
1757-6512 (ISSN-L)
OpenAlex
W2110062590
Cited by
126
References
12
FWCI
6.57
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.